

**Australian Government** 

# **Department of Health**

# Therapeutic Goods Administration

### **Public Summary**

Summary for ARTG Entry:	231823	KeenMind
ARTG entry for	Medicine Listed	
Sponsor	SFI Australasia	
Postal Address	PO Box 1027, CF Australia	ROWS NEST, NSW, 1585
ARTG Start Date	15/12/2014	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

## Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

#### Products

1 . KeenMind						
Product Type	Single Medicine Product	Effective Date	18/10/2019			
Permitted Indicati	ons					
ntioxidant/Reduce	e free radicals formed in the body					
lelps reduce/decre	ease free radical damage to body cells					
aditionally used in	n Ayurvedic medicine to medhya/brain tonic/	improve memory and cognition				
raditionally used in	n Ayurvedic medicine to maintain/support ca	rdiovascular system health				
raditionally used in	n Ayurvedic medicine to adaptogen/Help boo	ly adapt to stress				
Relieve irritability						
Soothe/calm nerve	S					
Decrease/reduce/re	elieve symptoms of stress					
ecrease/reduce/re	elieve nervous tension/unrest					
ecrease/reduce/re	elieve symptoms of mild anxiety					
lelps enhance/imp	rove/promote/increase attention span					
Decrease/reduce m	nental/cognitive fatigue					
/laintain/support m	ental concentration/focus/clarity					
Inhance/improve/p	promote/increase cognitive performance					
Enhance/improve/p	promote/increase mental endurance/stamina					
/laintain/support m	ental endurance/stamina					
/laintain/support co	ognitive function/mental function					
raditionally used in	n Ayurvedic medicine to maintain/support lea	arning and information processing				
/laintain/support le	arning and information processing					

#### Page 1 of 2

#### This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information



**Australian Government** 

### **Department of Health**

Therapeutic Goods Administration

Traditionally used in Ayurvedic medicine to enhance/improve/promote learning ability/function

Enhance/improve/promote learning ability/function

Enhance/improve/promote/increase mental alertness/wakefulness

Enhance/improve/promote/increase memory/recall

Maintain/support memory/mental recall

Enhance/improve/promote/increase short term memory

Maintain/support general mental wellbeing

Maintain/support brain function

Maintain/support brain health

Traditionally used in Ayurvedic medicine to nerve tonic

Helps enhance/promote healthy nerve conduction/transmission/neurotransmission

### Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must only refer to mild anxiety.

If Ayurvedic terminology is used on medicine label, label statement: Talk to a Ayurvedic practitioner/health professional if you are unsure if this medicine is right for you.

Product presentation must not imply or refer to serious cardiovascular conditions.

# Standard Indications

No Standard Indications included on Record

**Specific Indications** 

No Specific Indications included on Record

#### Warnings

No Warnings included on Record

**Additional Product information** 

# Pack Size/Poison information

Pack Size		Poison Schedule		
Components				
1. Formulation 1				
Dosage Form Ca	psule, hard			
Route of Administration Or	al			
Visual Identification				
Active Ingredients				
Bacopa monnieri whole plant Extract dry concentrate			160 mg	
Equivalent: Bacopa monnieri (Dry)			2.16 g	
Other Ingredients (Excipients)				
calcium hydrogen phosphate				
chlorophyllin-copper complex				
colloidal anhydrous silica				
hypromellose				
magnesium stearate				
microcrystalline cellulose				
purified talc				
titanium dioxide				

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Page 2 of 2

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information